U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07207824) titled 'DV+BCG in HER2-Expressing, BCG-Naive High-Risk NMIBC' on Sept. 28.
Brief Summary: The purpose of this study is to learn about the safety and effects of the study medicine (Disitamab Vedotin) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, and is high risk. Each participant was assigned to one of two study treatment groups: One group is given Disitamab Vedotin and BCG.The second group is given BCG only and will not receive Disitamab Vedotin.
Study Start Date: Dec. 01
Study Type: I...